Dataset ID: 6
Dataset Details
Study Design
| Study Design Background |
Assessment of the uptake of a novel CXCR-4 directed radiolabelled peptide in naive and tumor bearing animals.
|
|---|---|
| Study Description |
CXCR4
|
| Study Type |
Preclinical
|
| Study Subtype |
In vitro and in vivo
|
Publication
| Paper Linked |
Yes
|
|---|---|
| Paper Title |
D-Peptide-Based Probe for CXCR4-Targeted Molecular Imaging and Radionuclide Therapy
|
| Paper Authors |
Kaat Luyten(1), Tom Van Loy(256), Christopher Cawthorne(3), Christophe M. Deroose(3), Dominique Schols(256), Guy Bormans(1) and Frederik Cleeren(1)
|
| Affiliation |
Laboratory for Radiopharmaceutical Research, Department of Pharmaceutical and Pharmacological Sciences, KU Leuven; Laboratory of Virology and Chemotherapy, Department of Microbiology, Immunology and Transplantation, KU Leuven; Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven;3000 Leuven, Belgium
|
| Paper Journal |
Pharmaceutics
|
| Paper Year |
2022
|
| Paper DOI | |
| Open Access |
Yes
|
Study Component
| Multi Modality Images |
Yes
|
|---|---|
| Imaging Modality |
PET CT
|
| Radiation |
Yes
|
| Imaging Coverage |
Whole body
|
| Imaging Target |
CXCR4
|
Dataset Information
| Institution |
KU Leuven
|
|---|---|
| PI |
Frederik Cleeren
|
| Country Of Institution |
Belgium
|
| Imaging Facility |
Molecular Small Animal Imaging Centre (MoSAIC), KU Leuven
|
| Euro Bio Imaging Node |
Flanders Bio Imaging (Candidate EuBI node)
|
| Country Of Imaging Facility |
Belgium
|
In Vivo Experimental Parameters
| Number Of Groups |
2
|
|---|---|
| Types Of Groups |
Tumour bearing animals - + CXCR4 blocking drug
|
| Overall Sample Size |
9
|
| Disease Model |
Cancer
|
| Organ Or Tissue |
Tumour, liver
|
| Sample Size For Each Group |
4 animals for tracer uptake, 4 animals for tracer uptake + blocking compound
|
| Power Calculation |
The number of animals included in the study was based on previous reports where an approximately 70% difference was seen between naïve and blocked animals in CXCR4 expressing organs [https: jnm.snmjournals.org content 61 1 123]. Detection of such difference therefore required 3 animals per group (power = 0.95 and a = 0.05) assuming a 20% standard deviation within the groups.
|
| Randomization |
Yes. All animals included in the study were randomly selected among tumour bearing mice with tumours at size.
|
| Blinding |
No
|
| Outcome Measures |
Time activity curves showing uptake in tumour and liver over the 1hr scan period - + blocking agent
|
| Statistical Methods |
One tail t-test for independent groups assuming unequal variances
|
| Species |
Mice
|
| Strain |
SCID Bg
|
| Immune Status |
Immunodeficient
|
| Sex |
Female
|
| Age |
6-8 weeks on arrival
|
| Age At Start Experiment |
13 weeks
|
| Age At Scanning Experiment S |
18-21 weeks
|
| Weight At Start Experiment |
22-24g
|
| Weight At End Experiment |
22-24g
|
| Gene |
CB17.Cg-Prkdcscid Lystbg-J Crl
|
| Source Of Animals |
Charles River (Sulzfeld, Germany)
|
Experimental Procedures
| Pharmacological Procedures Intervention And Control |
Yes
|
|---|---|
| Pharmacological Drug |
AMD3100
|
| Formulation |
PBS
|
| Drug Dose |
5mg kg
|
| Site Or Route Of Administration |
Iv
|
| Frequency Of Administration |
Once, at the start of scanning
|
| Vehicle Or Carrier Solution Formulation |
PBS
|
| Blood Sampling |
No
|
| Surgical Procedures Including Sham Surgery |
No
|
| Pathogen Infection Intervention And Control |
No pathogens used
|
| Analgesic Plan To Relieve Pain Suffering And Distress |
No
|
| Anesthesia Type |
Gas
|
| Duration |
75-90
|
| Anesthesia Drugs |
Isoflurane
|
| Anesthesia Dose |
1-2%
|
| Monitoring Regime |
Respiratory and temperature monitoring whilst scanning, visual surveillance during preparation and recovery
|
| Euthanasia |
Yes
|
| Method |
Cervical dislocation
|
| Histology |
No
|
| Frequency Of Imaging |
Single scan
|
| Timing Of Imaging |
Animals scanned in accordance with radiotracer production schedule
|
| Overall Scan Length |
60 minute PET + CT
|
| Contrast Agent Or Radio Isotope Or Challenge With Gas Molecule |
Yes
|
| Contrast Agent Commercial Drug |
None, Pentixafor
|
| Contrast Agent Chemical Drug |
[18F]AlF-NOTA-DV1-k-(DV3),
|
| Contrast Agent Dose |
1.5-3.0MBq
|
| Injection Volume |
0.10ml
|
| Injection Time |
8-10 seconds
|
| Vehicle |
Saline
|
| Route Of Administration |
Intravenous
|
| Cell Lines |
Yes
|
| Cell Line |
U87.CXCR4
|
| Provenance |
Collaborator
|
| Cell Injection Route |
Subcutaneous implant
|
| Number Of Cells |
1x106 in 50% Geltrex
|
| Name Of Reagent |
Geltrex
|
| Frequency Of Experimental Procedures |
Single implant of tumour cells at start of experiment; tumours measured via caliper every 2-3 days
|
| Timing Of Experimental Procedures |
Implants occured early afternoon, tumour measures in the morning.
|
| Frequency Of Experimental Measurements |
See above
|
| Timing Of Experimental Measurements |
See above
|
| Housing Room |
Not SPF
|
| Respiration Rate |
Only during scanning
|
| Body Tempurature Etc |
Only during scanning
|
| Food Intake Measured |
No
|
Image Acquisition
| Instrument Vendor |
Molecubes
|
|---|---|
| Instrument Type |
Î’-cube, X-cube
|
| Instrument Specifics |
PET- Axial FOV 130 mm, Transaxial FOV 72 mm, Resolution 850 µm, Peak Sensitivity > 12 %, Energy Resolution 12,6 %, LYSO cont. SiPM CT: cone-shaped X-ray beam and detector, tungsten anode source with focal spot size of 33µm.
|
| Image Acquisition Parameters |
PET- 60 minute dynamic acquisition, Energy window 434-588 KeV. CT: 50 k Vp, 480 exposures, 85 ms projection, 100 µA tube current, rotation time 60 s, 0.8mm Al beam filtration.
|
| Correction |
PET- Decay, Attenuation, Scatter, Dead time, Randoms corrected. Non-uniform radial sampling corrected, sensitivity calibrated against dose calibrator, detectors normalized.
|
| Raw Data |
No
|
| QA/QC |
Regular QA QC carried out on scanners, which are under service contract
|
Image Data
| Image Type |
Processed images (reconstructed PET and CT data)
|
|---|---|
| Image Scale |
HU for CT, SUV for PET
|
| Format Compression |
DICOM
|
| Dimensions |
3D
|
| Overall Number Of Images |
6 x PET, 6 x CT for original images, 9 individual images
|
| Field Of View |
70x70x124.8 (CT); 76.8x76.8x 153.6 (PET) for multiple animal image; individual cropped images vary
|
| Dimension Extents |
350x350x624 (CT); 192x192x384 (PET) for multiple animal image; individual cropped images vary
|
| Size Description |
70x70x124.8 (CT); 76.8x76.8x 153.6 (PET) for multiple animal image; individual cropped images vary
|
| PI xel Voxel Size Description |
0.2mm (CT), 0.4mm (PET)
|
| Image Processing Methods |
Images reconstructed as below.
|
| Image Reconstruction Algorithm |
OSEM (PET), 30 iterations. Iterative (CT)
|
| QC Info |
QC- high (injections all successful as evidenced by dynamic images)
|
| Corrections |
Corrections listed above
|
Image Correlation
| Spatial And Temporal Alignment |
PET and CT images aligned using rigid registration in PMOD 4.0.
|
|---|---|
| Coregistered Images |
Dataset includes coregistered datasets for individual animals
|
| Transformation Matrix Other Info |
Transformation matrix not saved, but original multiple-animal images available
|
| Related Images And Relationship |
PET and CT images aligned using rigid registration in PMOD 4.0.
|
Analyzed Data
| Analysis Result Type |
Numerical
|
|---|---|
| Data Used For Analysis |
Time activity curves generated by manual delineation of tumour and a sphere centred on the liver, scaled to SUV
|
| Analysis Method And Details |
Manual delineation of tumour placement of spherical ROIs in PMOD v 4.0.
|
| Status |
Complete
|
| Updated Year |
2022
|